Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data
- PMID: 34289097
- DOI: 10.1111/bjd.20658
Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data
Abstract
Background: The German programme for skin cancer screening was established in 2008 with the aim of reducing skin cancer mortality. However, the effectiveness and risk-benefit ratio of the programme remain unclear.
Objectives: To compare the mortality rates of patients with melanoma who participate in a screening programme to those who do not.
Methods: A retrospective cohort study, based on pseudonymized health insurance data of 1 431 327 individuals from Saxony, Germany, was conducted for the period 2010-2016. Patients with prevalent and incident melanoma were defined based on diagnosis, medical procedures and prescriptions. Patients who underwent screening and had a first diagnosis of melanoma within 2 years of screening were assigned to the intervention group. Relative survival and Cox regression were used to assess potential differences in mortality.
Results: We identified 4552 individuals with prevalent and 2475 individuals with incident melanoma. The percentage of screening participants (n = 1801) who had locoregional (4·2% vs. 13·5%) and/or distant metastases (4·3% vs. 8·0%), or who were treated with systemic anticancer therapies (11·6% vs. 21·8%) was lower vs. nonparticipants (n = 674). Screening participants had significantly better survival rates. The unadjusted Cox model gave a hazard ratio (HR) of 0·37 [95% confidence interval (CI) 0·30-0·46]. After adjusting for named confounders, the effect remained (HR 0·62, 95% CI 0·48-0·80).
Conclusions: Patients who participated in the screening programme had lower mortality than those who had not undergone screening. However, these findings may result from a healthy screen bias and/or overdiagnosis associated with screening, and not from the screening itself.
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Comment in
-
Benefits of a nationwide population-based skin cancer screening programme - still a controversial debate.Br J Dermatol. 2022 Jan;186(1):8-9. doi: 10.1111/bjd.20709. Epub 2021 Oct 4. Br J Dermatol. 2022. PMID: 34605008 No abstract available.
-
Positive Effect on Prognostic Factors.Dtsch Arztebl Int. 2023 Aug 21;120(33-34):561. doi: 10.3238/arztebl.m2023.0081. Dtsch Arztebl Int. 2023. PMID: 37732596 Free PMC article. No abstract available.
Similar articles
-
Screening for reducing morbidity and mortality in malignant melanoma.Cochrane Database Syst Rev. 2019 Jun 3;6(6):CD012352. doi: 10.1002/14651858.CD012352.pub2. Cochrane Database Syst Rev. 2019. PMID: 31157404 Free PMC article.
-
Effects of the German skin cancer screening programme on melanoma incidence and indicators of disease severity.Br J Dermatol. 2016 Nov;175(5):912-919. doi: 10.1111/bjd.14758. Epub 2016 Sep 6. Br J Dermatol. 2016. PMID: 27203791
-
Association Between Health Maintenance Practices and Skin Cancer Risk as a Possible Source of Detection Bias.JAMA Dermatol. 2019 Mar 1;155(3):353-357. doi: 10.1001/jamadermatol.2018.4216. JAMA Dermatol. 2019. PMID: 30586131 Free PMC article.
-
Systematic skin cancer screening in Northern Germany.J Am Acad Dermatol. 2012 Feb;66(2):201-11. doi: 10.1016/j.jaad.2010.11.016. Epub 2011 Nov 8. J Am Acad Dermatol. 2012. PMID: 22074699
-
Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2023 Apr 18;329(15):1296-1307. doi: 10.1001/jama.2023.3262. JAMA. 2023. PMID: 37071090
Cited by
-
One-year follow-up healthcare costs of patients diagnosed with skin cancer in Germany: a claims data analysis.BMC Health Serv Res. 2022 Jun 11;22(1):771. doi: 10.1186/s12913-022-08141-9. BMC Health Serv Res. 2022. PMID: 35690746 Free PMC article.
-
Opportunities to inform German residents about the possibility of skin cancer screening and to inform stakeholders to take appropriate actions: A qualitative approach.Cancer Med. 2023 May;12(9):10829-10839. doi: 10.1002/cam4.5717. Epub 2023 Apr 16. Cancer Med. 2023. PMID: 37062065 Free PMC article.
-
Evaluating the Frequency of Mole Checks by a Dermatologist and Correlated Variables in a Global Survey across 17 Countries: HELIOS Project.Acta Derm Venereol. 2024 Aug 23;104:adv40929. doi: 10.2340/actadv.v104.40929. Acta Derm Venereol. 2024. PMID: 39177162 Free PMC article.
-
The effect of screening on melanoma incidence and biopsy rates.Br J Dermatol. 2022 Oct;187(4):515-522. doi: 10.1111/bjd.21649. Epub 2022 Jun 28. Br J Dermatol. 2022. PMID: 35531668 Free PMC article.
-
Evaluation of a Population-Based Targeted Screening Approach for Skin Cancer with Long-Time Follow-Up in Austria including Potential Effects on Melanoma Mortality.Cancers (Basel). 2024 Mar 26;16(7):1283. doi: 10.3390/cancers16071283. Cancers (Basel). 2024. PMID: 38610961 Free PMC article.
References
-
- Apalla Z, Lallas A, Sotiriou E et al. Epidemiological trends in skin cancer. Dermatol Pract Concept 2017; 7:1-6.
-
- Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther (Heidelb) 2017; 7(Suppl. 1):5-19.
-
- Matthews NH, Li WQ, Qureshi AA et al. Epidemiology of Melanoma. Brisbane: Codon Publications, 2017.
-
- Riker AI, Zea N, Trinh T. The epidemiology, prevention, and detection of melanoma. Ochsner J 2010; 10:56-65.
-
- Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 2016; 136:1161-71.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical